[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Covered Call Screener Results for August 4th

Covered calls are a great strategy to add to any portfolio, and can offer enhanced yield from stock holdings, in some case, that can be a significant increase.

To trade a covered call we need to own (or buy) 100 shares of a stock and then sell a call option against that stock position.

Fundamentals

See More
  • Market Capitalization, $K 315,569,408
  • Shares Outstanding, K 2,469,824
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 12,969 M
  • EBITDA $ 18,807 M
  • 60-Month Beta 0.19
  • Price/Sales 4.95
  • Price/Cash Flow 11.36
  • Price/Book 6.98

Options Overview Details

View History
  • Implied Volatility 30.11% (-4.60%)
  • Historical Volatility 29.98%
  • IV Percentile 59%
  • IV Rank 61.37%
  • IV High 35.42% on 04/27/26
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 3) 5.40 (4.23%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 2,432
  • Volume Avg (30-Day) 19,536
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 441,220
  • Open Int (30-Day) 434,366
  • Expected Range 122.18 to 132.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.26
  • Number of Estimates 3
  • High Estimate $-0.21
  • Low Estimate $-0.36
  • Prior Year $2.13
  • Growth Rate Est. (year over year) -112.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.16 +6.18%
on 07/14/26
135.05 -5.53%
on 07/28/26
-1.98 (-1.53%)
since 07/02/26
3-Month
110.94 +15.00%
on 05/15/26
135.05 -5.53%
on 07/28/26
+14.47 (+12.79%)
since 05/04/26
52-Week
77.58 +64.45%
on 09/25/25
135.05 -5.53%
on 07/28/26
+47.72 (+59.75%)
since 08/04/25

Most Recent Stories

More News
Covered Call Screener Results for August 4th

Covered Call Screener Results for August 4th

TGT : 147.77 (-1.06%)
OXY : 54.49 (-1.77%)
SBUX : 102.46 (-0.88%)
MRK : 129.57 (+1.41%)
SCHW : 105.58 (-0.27%)
Merck (NYSE:MRK) Posts Better-Than-Expected Sales In Q2 CY2026

Merck (NYSE:MRK) Posts Better-Than-Expected Sales In Q2 CY2026

MRK : 129.57 (+1.41%)
Merck: Q2 Earnings Snapshot

Merck: Q2 Earnings Snapshot

MRK : 129.57 (+1.41%)
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Sales Growth Reflects Continued Strength in Oncology, Including Initial Uptake of KEYTRUDA QLEX, and Animal Health, Plus Contributions From Launches Such as WINREVAIR ...

MRK : 129.57 (+1.41%)
Option Volatility And Earnings Report For Aug 3 - 7

It is another big week on the earnings front with a lots of big name companies reporting. This week could make or break the market. This week we have SpaceX, Advanced Micro Devices, Palantir Technologies,...

MSTR : 93.99 (-0.92%)
NVDA : 210.09 (+1.67%)
ANET : 189.08 (+2.27%)
AAPL : 304.99 (+0.52%)
SNDK : 1,389.77 (+7.90%)
MRK : 129.57 (+1.41%)
MCD : 268.73 (+1.32%)
DIS : 97.99 (-0.15%)
SHOP : 118.75 (+1.49%)
TSLA : 321.83 (-0.08%)
SPCX : 117.17 (+2.31%)
CAT : 885.00 (+6.62%)
What To Expect From Merck’s (MRK) Q2 Earnings

What To Expect From Merck’s (MRK) Q2 Earnings

MRK : 129.57 (+1.41%)
Jobs Numbers Set for Release Next Week

Monday U.S. Economic Lookahead S&P final U.S. manufacturing PMI (July) ISM manufacturing ...

SONY : 22.39 (-1.06%)
SNDK : 1,389.77 (+7.90%)
COP : 117.09 (-1.74%)
NVO : 47.44 (+0.74%)
CAT : 885.00 (+6.62%)
MRK : 129.57 (+1.41%)
VRTX : 487.74 (+3.62%)
AMD : 513.40 (+5.93%)
LLY : 1,129.13 (+0.69%)
PH : 983.60 (-1.40%)
PLTR : 153.18 (+21.91%)
MAR : 343.74 (-0.89%)
Earnings, PMI and Other Key Things to Watch this Week

Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide...

APP : 415.10 (+2.20%)
ANET : 189.08 (+2.27%)
SPOT : 487.98 (+0.34%)
SNDK : 1,389.77 (+7.90%)
MRK : 129.57 (+1.41%)
PFE : 25.19 (+0.64%)
MCD : 268.73 (+1.32%)
DIS : 97.99 (-0.15%)
SHOP : 118.75 (+1.49%)
SPCX : 117.17 (+2.31%)
CAT : 885.00 (+6.62%)
AMD : 513.40 (+5.93%)
1 Cash-Producing Stock with Promising Prospects and 2 That Underwhelm

1 Cash-Producing Stock with Promising Prospects and 2 That Underwhelm

VIAV : 39.72 (+5.22%)
MRK : 129.57 (+1.41%)
ALGM : 43.15 (+3.93%)
Merck Announces Fourth-Quarter 2026 Dividend

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock...

MRK : 129.57 (+1.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 135.34
2nd Resistance Point 133.40
1st Resistance Point 130.59
Last Price 129.57
1st Support Level 125.84
2nd Support Level 123.90
3rd Support Level 121.09

See More

52-Week High 135.05
Last Price 129.57
Fibonacci 61.8% 113.10
Fibonacci 50% 106.32
Fibonacci 38.2% 99.53
52-Week Low 77.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.